CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 34 enrolled
Drug / intervention
Pseudoephedrinedrug
Likely dose
Pseudoephedrine 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00704496
NCT00704496Phase 3Completed
CompareCT.gov

The Effect of Pseudoephedrine on Rhinitis and Sleep

Milton S. Hershey Medical Center·interventional·Posted Jun 25, 2008·Updated Oct 18, 2017

In Brief

A Phase 3 clinical trial evaluating Pseudoephedrine for Rhinitis and Sleep. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a decongestant, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation in individuals with year round perennial allergic rhinitis (PAR). This decrease in sleep fragmentation will reduce daytime somnolence and fatigue.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Sleep
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 25, 2008
Enrollment StartJun 1, 2007
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.0 years ago

Interventions

Pseudoephedrinedrug

Pseudoephedrine is a 240 mg PO per day